Stock Screener App

Gratuito -

Installare

14.40

0.63% 0.09

after-market

Dopo l'orario di chiusura: 14.25 -0.15 -1.04%

Ultragenyx Pharmaceutical Inc (RARE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RARE Giù? Forum Previsione Frazionamento azionario

Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie

Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx’s GTX-102 failure erases pipeline sales expectations - S&P Global

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits

Ultragenyx SVP Theodore Huizenga sells $2,252 in shares By Investing.com - Investing.com South Africa

Why Did RARE Stock Slump 46% After-Hours? - Stocktwits

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent

Ultragenyx SVP Theodore Huizenga sells $2,252 in shares - Investing.com

Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan

$Ultragenyx Pharmaceutical (RARE.US)$ get ready - Moomoo

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits

Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance

Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance

Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters

RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade

Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com

Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade

RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com

The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

This week in charts: China deals, stock flatlines and Lilly’s M&A spree - BioPharma Dive

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat

Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media

Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

Ultragenyx Pharma Is Maintained at Overweight by Barclays - Moomoo

Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat

Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - kavout.com

Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st

Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat

Ultragenyx Pharma Cut to Market Perform From Outperform by William Blair - Moomoo

Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha

Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive

Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com

Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News

Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat

Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb

Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target - Benzinga

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat

Angelman wings clipped by Ultragenyx phase III bust - BioWorld News

Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International

Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena

Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha

Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance

RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView

Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive

Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative

Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial - Pharmaceutical Executive

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 12-Month Low After Analyst Downgrade - MarketBeat

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $23.00 at Wedbush - marketbeat.com

Ultragenyx to slash costs after Angelman trial failure - pharmaphorum

We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more - STAT

RARE Stock Craters As Ultragenyx Slashes Outlook After Trial Failure - timothysykes.com

RARE Stock Craters As Aspire Trial Failure Triggers Reset - StocksToTrade

William Blair Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Market Perform - MarketBeat

Why Is Ultragenyx Stock Tumbling Today?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga

RARE Stock Collapses After Angelman Drug Fails Late-Stage Trial - StocksToTrade

Canaccord cuts Ultragenyx stock price target on trial failure - Investing.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $33.00 at Cantor Fitzgerald - MarketBeat

HC Wainwright Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat

Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Neutral Rating by JPMorgan Chase & Co. - MarketBeat

Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to In-Line at Evercore - MarketBeat

Wells Fargo cuts Ultragenyx Pharma price target on trial failure By Investing.com - Investing.com Nigeria

Ultragenyx Angelman syndrome drug fails Phase III test - The Pharma Letter

Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review - BioSpace

William Blair Downgrades Ultragenyx Pharmaceutical to Market Perform From Outperform - marketscreener.com

Evercore ISI Downgrades Ultragenyx Pharmaceutical to In Line From Outperform, Adjusts Price Target to $16 From $34 - marketscreener.com

Baird Downgrades Ultragenyx Pharmaceutical to Neutral From Outperform, Adjusts Price Target to $16 From $40 - marketscreener.com

Wells Fargo cuts Ultragenyx Pharma price target on trial failure - Investing.com

RPRX

$58.75

3.04%

INSM

$127.28

1.18%

ROIV

$40.94

2.08%

ALNY

$247.51

4.07%

ONC

$341.80

2.62%

RVMD

$203.35

2.08%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters